Table 4.
Major adverse events during follow-up
| Complications and adverse events | All | Non-CKD (stages I + II) | CKD (stages III + IV + V) | P value |
|---|---|---|---|---|
| N = 300 | 149 | 151 | ||
| Thrombosis event, n (%) | 11 (3.7) | 8 (5.4) | 3 (2.0) | 0.137 |
| Ischemic stroke, n (%) | 3 (1.0) | 2 (1.3) | 1 (0.7) | 0.621 |
| Transient ischemic attack, n (%) | 8 (2.7) | 6 (4.0) | 2 (1.3) | 0.172 |
| Systemic thromboembolism, n (%) | 0 | 0 | 0 | 1.0 |
| Device-related thrombosis, n (%) | 13 (4.3) | 8 (5.4) | 5 (3.3) | 0.411 |
| GAP (> 5 mm), n (%) | 2 (1.3) | 2 (0.7) | 0 | 0.246 |
| Major bleeding, n (%) | 19 (6.3) | 9 (6.0) | 10 (6.6) | 1.0 |
| Cerebral hemorrhage, n (%) | 4 (1.3) | 2 (1.3) | 2 (1.3) | 1.0 |
| Gastrointestinal bleeding, n (%) | 10 (3.3) | 4 (2.7) | 6 (4.0) | 0.75 |
| Other bleeding, n (%) | 5 (1.7) | 3 (2.0) | 2 (1.3) | 0.683 |
| Other clinical status, n (%) | 58 (19.3) | 19 (6.3) | 39 (25.8) | 0.005 |
| Pace maker, n (%) | 18 (6.0) | 6 (4.0) | 12 (7.9) | 0.224 |
| Tumor, n (%) | 7 (2.3) | 2 (1.3) | 5 (3.3) | 0.448 |
| Wound, n (%) | 17 (5.7) | 7 (4.7) | 10 (6.6) | 0.619 |
| Operation, n (%) | 16 (5.3) | 4 (2.7) | 12 (7.9) | 0.069 |
| Total all-cause death/total patients, n (%) | 35 (11.7) | 12 (8.1) | 23 (15.2) | 0.071 |
| Death/successful LAAC, n (%) | 32 (10.7) | 11 (7.4) | 21 (13.9) | 0.091 |
| Cardiac death/successful LAAC, n (%) | 5 (1.7) | 2 (1.3) | 3 (2.0) | 1.0 |
| Non-cardiac death/successful LAAC, n (%) | 27 (9.0) | 9 (6.0) | 18 (11.9) | 0.105 |
| Device-related death/successful LAAC, n (%) | 0 | 0 | 0 | 1.0 |